(73) showed that CRISPR/cas9 KO of granulocyte-macrophage colony-stimulating factor (GM-CSF) decreased the side effects like cytokine release syndrome and neuroinflammation of CAR-T cell therapies and also improved the CAR-T cell anti-tumor activity in-vivo (73). This evidence concerns the gene CSF2 and neoplasm.